

Oncology Today with Dr Neil Love
Dr. Neil Love
Medical oncologist Dr Neil Love interviews clinical investigators on new research and practical application to general medical oncology practice.
Episodes
Mentioned books

Oct 20, 2025 • 57min
Metastatic Breast Cancer — Current and Future Integration of Antibody-Drug Conjugates
Dr Aditya Bardia and Dr Adam M Brufsky discuss published and emerging datasets investigating the incorporation of antibody-drug conjugates into the treatment of metastatic breast cancer.CME information and select publications here.

Oct 18, 2025 • 25min
Lung Cancer — 5-Minute Journal Club Issue 3 with Dr Aaron Lisberg: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Aaron Lisberg from the University of California, Los Angeles discusses recent developments with TROP2-directed antibody-drug conjugates in the management of non-small cell lung cancer. CME information and select publications here.

Oct 17, 2025 • 58min
Non-Hodgkin Lymphoma — The Implications of Recent Datasets for Current and Future Disease Management
Dr Carla Casulo from Wilmot Cancer Institute in Rochester, New York, and Dr Brad S Kahl from Siteman Cancer Center in St Louis, Missouri, review recent datasets and their significance for the management of various forms of non-Hodgkin lymphoma. CME information and select publications here.

Oct 13, 2025 • 44min
HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment
Dr Laura Huppert from the University of California, San Francisco, discusses approved and investigational antibody-drug conjugates in the current and future management of HR-positive and triple-negative metastatic breast cancer. CME information and select publications here.

Oct 10, 2025 • 60min
Follicular Lymphoma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
Dr Jeremy S Abramson from Massachusetts General Hospital in Boston, Dr Jennifer Crombie from Dana-Farber Cancer Institute also in Boston and Dr Laurie H Sehn from the BC Cancer Centre for Lymphoid Cancer in Vancouver, British Columbia, Canada, discuss recent updates on available and novel treatment strategies for follicular lymphoma. CE information and select publications here.

Oct 8, 2025 • 59min
Acute Myeloid Leukemia — An Interview with Dr Ghayas Issa on the Role of Menin Inhibitors
Dr Ghayas Issa from The University of Texas MD Anderson Cancer Center in Houston discusses data guiding the use of menin inhibitors for patients with acute myeloid leukemia and select alterations. CME information and select publications here.

Oct 6, 2025 • 1h 2min
Breast Cancer — An ASCO 2025 Review
Dr Sara A Hurvitz and Dr Sara M Tolaney summarize the treatment landscape for breast cancer and discuss the implications of clinical findings recently presented at the 2025 ASCO Annual Meeting. CME information and select publications here.

Oct 2, 2025 • 58min
Relapsed/Refractory Multiple Myeloma — Proceedings from a Session Held During the Society of Hematologic Oncology 2025 Annual Meeting
Prof Meletios-Athanasios (Thanos) C Dimopoulos from Alexandra Hospital in Athens, Greece, Dr Hans Lee from Sarah Cannon Research Institute in Nashville, Tennessee, Dr Joseph Mikhael from City of Hope Cancer Center in Phoenix, Arizona, and Dr Noopur Raje from Massachusetts General Hospital in Boston discuss recent updates on available and novel treatment strategies for relapsed/refractory multiple myeloma. CE information and select publications here.

Sep 26, 2025 • 22min
Breast Cancer — 5-Minute Journal Club Issue 3 with Dr Kevin Kalinsky: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
Dr Kevin Kalinsky from the Winship Cancer Institute of Emory University in Atlanta, Georgia, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of breast cancer. CME information and select publications here.

Sep 22, 2025 • 41min
Metastatic BRCA-Negative, Triple-Negative Breast Cancer — An Interview with Prof Peter Schmid on Optimal Management
Prof Peter Schmid from Barts Cancer Institute in London reviews available efficacy and safety data guiding the optimal management of metastatic triple-negative breast cancer. CME information and select publications here.


